Neurimmune is a biopharmaceutical company translating human immune memory into transformative antibody therapeutics. Neurimmune discovered aducanumab together with a team of researchers at the University of Zurich and licensed it to Biogen. Aducanumab is a human monoclonal antibody against beta amyloid in development for the treatment of early Alzheimer's disease. Based on large Phase 3 study results, Biogen decided to proceed with regulatory filings for approval. Besides aducanumab, Neurimmune discovered with its Reverse Translational Medicine technology cinpanemab for Parkinson's disease, the anti-tau antibody BIIB076 for Alzheimer's disease, the anti-miSOD1 antibody AP-101 for ALS and the anti-ATTR antibody NI006 for cardiomyopathy, these programs are currently evaluated in clinical trials.